- Multipotent mesenchymal stromal cells in articular diseasesChristian Jorgensen
INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, Montpellier F 34091, France
Best Pract Res Clin Rheumatol 22:269-84. 2008..This chapter focuses on the potential of MSC to repair cartilage, with an emphasis on the factors that are known to be required in inducing chondrogenesis and on their immunosuppressive potential...
- Mesenchymal stem cells and rheumatoid arthritisChristian Jorgensen
Immunorheumatology Department, Lapeyronie Hospital, 34295 Montpellier Cedex 5, France
Joint Bone Spine 70:483-5. 2003
- miRNAs and rheumatoid arthritis - promising novel biomarkersIsabelle Duroux-Richard
INSERM U844, CHU Saint Eloi, bâtiment INM, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
Swiss Med Wkly 141:w13175. 2011..As a growing body of evidences reveals abnormal expression of specific miRNAs in RA tissues, the use of a blood-based miRNA signature for optimal diagnosis and treatment becomes a realistic option...
- Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritisIsabelle Duroux-Richard
INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5, France Université Montpellier I, UFR de Medecine, Boulevard Henri IV, 34090 Montpellier, France
Mediators Inflamm 2014:342524. 2014..Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment. ..
- [Multipotent stromal cells: controversial impact on tumor development and metastasis]Florence Apparailly
INSERM, U844, INM, Hopital Saint Eloi, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
Med Sci (Paris) 24:359-60. 2008
- MicroRNAs as new player in rheumatoid arthritisIsabelle Duroux-Richard
INSERM, U844, CHU Saint Eloi, bâtiment INM, 80, rue Augustin Fliche, 34295 Montpellier Cedex 5, France
Joint Bone Spine 78:17-22. 2011..Here, we provide an overview of the state-of-the-art on miRNAs in RA, focusing on both systemic and local features of the pathology...
- Leflunomide-induced aseptic meningitisJean David Cohen
Immuno Rheumatology Department, Hopital Lapeyronie, 34295 Montpellier Cedex 5, France
Joint Bone Spine 71:243-5. 2004..Drug-induced aseptic meningitis is uncommon and occurs primarily in patients with autoimmune disease. We report the first known case of leflunomide-induced aseptic meningitis, in a patient with rheumatoid arthritis...
- Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cellsFarida Djouad
INSERM Unit 475, Montpellier, France
Arthritis Res Ther 7:R1304-15. 2005....
- Mesenchymal stem cells: an emerging tool for cancer targeting and therapyVanessa Fritz
INSERM U844, CHU Hôpital Saint Eloi Bâtiment INM, BP74103, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
Curr Stem Cell Res Ther 3:32-42. 2008..This review highlights recent works and potential clinical applications of MSCs in this field...
- Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytesCaroline Desmetz
Institut de Génétique Humaine du CNRS UPR1142, Montpellier, F 34000, France
Clin Immunol 123:148-54. 2007..The CCR5 density on T cell surface, which is constant over time for a given individual, but varies drastically from one individual to another, might thus be a factor determining the intensity of joint inflammation in the course of RA...
- Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005Alan Tyndall
Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH 4012, Switzerland
Arthritis Res Ther 9:301. 2007..This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts...
- Multipotent mesenchymal stromal cells and immune toleranceDaniele Noel
Universite Montpellier 1, Montpellier, France
Leuk Lymphoma 48:1283-9. 2007..Finally, the data obtained from in vivo experimentation in various animal models as well as potential therapeutic applications will be presented...
- RNAi in arthritis: prospects of a future antisense therapy in inflammationMaroun Khoury
Inserm U 844, INM Hôpital Saint Eloi, BP 74103, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
Curr Opin Mol Ther 9:483-9. 2007..In addition, RNAi and current biotherapies used in the clinic are compared and contrasted...
- Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cellsBruno Delorme
INSERM, Equipe ESPRI EA 3855, Faculty of Medicine, University Francois Rabelais, 10 boulevard Tonnelle, Tours, France
Blood 111:2631-5. 2008..In addition, the expression of CD73, CD146, and CD200 was down-regulated in differentiated cells. The new marker CD200, because of its specificity and immunomodulatory properties, deserves further in-depth studies...
- Transient down-regulation of cbfa1/Runx2 by RNA interference in murine C3H10T1/2 mesenchymal stromal cells delays in vitro and in vivo osteogenesis, but does not overtly affect chondrogenesisJan O Gordeladze
Institute of Basal Medical Sciences, Department of Biochemistry, University of Oslo, Norway
Exp Cell Res 314:1495-506. 2008..These experiments indicate that a major transient reduction of cbfa1/Runx2 expression in MSCs is sufficient to delay osteoblastic differentiation, both in vitro and in vivo, while chondrogenesis seemed to be sustained...
- Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentialsDaniele Noel
INSERM U844, Montpellier, F 34091 France
Exp Cell Res 314:1575-84. 2008..In summary, our observations indicate that ADSC and MSC are fundamentally different cell types and differently committed cells...
- Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanismFarida Djouad
Institut National de la Sante et de la Recherche Medicale, U 844, Hopital Saint Eloi, Bât INM, 80 avenue Augustin Fliche, Montpellier, France
Stem Cells 25:2025-32. 2007..Disclosure of potential conflicts of interest is found at the end of this article...
- Engineered mesenchymal stem cells for cartilage repairFarida Djouad
INSERM, U 475, 99 rue Puech Villa, 34197 Montpellier Cedex 5, France
Regen Med 1:529-37. 2006..Here, we focus on the potential of MSCs to repair cartilage with an emphasis on the factors that are known to be required in inducing chondrogenesis...
- Gene therapy for rheumatoid arthritisNatacha Bessis
UPRES EA 3408 Université Paris 13 and Service de Rhumatologie CHU Avicenne, AP HP, Bobigny, France
J Gene Med 4:581-91. 2002..The best target remains to be determined and extensive research has to be conducted in preclinical studies...
- Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animalsFarida Djouad
INSERM U475, 99 rue Puech Villa, 34197 Montpellier Cedex 5, France
Blood 102:3837-44. 2003..Although the potential side effects of immunosuppression induced by MSCs have to be considered in further clinical studies, the usefulness of MSCs for various therapeutic applications still remains of great interest...
- Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cellsDaniele Noel
INSERM U475, Montpellier, France
Stem Cells 22:74-85. 2004....
- Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritisYea Lih Lin
Institut de Genetique Humaine, CNRS UPR1142, 34396 Montpellier Cedex 5, France
Hum Gene Ther 15:588-96. 2004..FIV vectors appear to be promising tools for biologic research and gene therapy...
- Tissue engineering through autologous mesenchymal stem cellsChristian Jorgensen
Service d Immuno Rhumatologie, Hopital Lapeyronie, 34295 Montpellier, Cedex 5, France
Curr Opin Biotechnol 15:406-10. 2004..The long-term behavior of MSCs associated with biomaterials and implanted in pathological joints remains to be investigated before clinical application in osteoarthritis or rheumatoid arthritis...
- Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritisFarida Djouad
INSERM U475, Montpellier, France
Arthritis Rheum 52:1595-603. 2005..Using a murine model of rheumatoid arthritis (RA), this study investigated whether the immunosuppressive properties of MSCs could be of therapeutic value to inhibit reactive T cells in autoimmune diseases such as RA...
- Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximabSylvie Fabre
Department of Immuno Rheumatology, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
J Rheumatol 32:2432-3. 2005..We describe a patient receiving infliximab who developed a primary cutaneous Nocardia otitidiscaviarum infection after a skin injury...
- Earlier onset of syngeneic tumors in the presence of mesenchymal stem cellsFarida Djouad
INSERM U475, Montpellier, France
Transplantation 82:1060-6. 2006..However, because of their immunosuppressive capacities, we investigated the effect of MSC on the development of syngeneic tumors...
- Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytesFarida Djouad
INSERM, U 844, 80 avenue Augustin Fliche, Montpellier, F 34091 France
Arthritis Res Ther 9:R33. 2007..Our data suggest that crosstalk between ECM components of the microenvironment and MSCs within the cartilage is responsible for the differentiation of MSCs into chondrocytes...
- Tissue engineering through mesenchymal stem cells: role of the Genostem ConsortiumChristian Jorgensen
Regen Med 1:493-6. 2006
- CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritisUrsula Mason
GlaxoSmithKline Pharmaceuticals, Greenford, Middlesex, UK
J Rheumatol 29:220-9. 2002..Double blind studies were conducted with the anti-CD4 monoclonal antibody (Mab) keliximab in patients with active, stable rheumatoid arthritis (RA), to confirm preliminary evidence of efficacy and safety from open. uncontrolled studies...